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ABSTRACT Candida albicans is a major cause of fungal diseases in humans, and its
resistance to available drugs is of concern. In an attempt to identify novel antifungal
agents, we initiated a small-scale screening of a library of 199 natural plant com-
pounds (i.e., natural products [NPs]). In vitro susceptibility proﬁling experiments iden-
tiﬁed 33 NPs with activity against C. albicans (MIC50s  32 g/ml). Among the se-
lected NPs, the sterol alkaloid tomatidine was further investigated. Tomatidine originates
from the tomato (Solanum lycopersicum) and exhibited high levels of fungistatic ac-
tivity against Candida species (MIC50s  1 g/ml) but no cytotoxicity against mam-
malian cells. Genome-wide transcriptional analysis of tomatidine-treated C. albicans
cells revealed a major alteration (upregulation) in the expression of ergosterol genes,
suggesting that the ergosterol pathway is targeted by this NP. Consistent with this
transcriptional response, analysis of the sterol content of tomatidine-treated cells
showed not only inhibition of Erg6 (C-24 sterol methyltransferase) activity but also
of Erg4 (C-24 sterol reductase) activity. A forward genetic approach in Saccharomyces
cerevisiae coupled with whole-genome sequencing identiﬁed 2 nonsynonymous mu-
tations in ERG6 (amino acids D249G and G132D) responsible for tomatidine resis-
tance. Our results therefore unambiguously identiﬁed Erg6, a C-24 sterol methyl-
transferase absent in mammals, to be the main direct target of tomatidine. We
tested the in vivo efﬁcacy of tomatidine in a mouse model of C. albicans systemic in-
fection. Treatment with a nanocrystal pharmacological formulation successfully de-
creased the fungal burden in infected kidneys compared to the fungal burden
achieved by the use of placebo and thus conﬁrmed the potential of tomatidine as a
therapeutic agent.
KEYWORDS antifungal agents, natural products, sterol biosynthesis, antifungal
therapy
Invasive fungal infections are an increasing threat to human health. In developedcountries, these infections predominantly occur in the context of increasingly ag-
gressive immunosuppressive therapies. The overall mortality from invasive diseases
caused by Candida and Aspergillus spp. is 30 to 50%, despite the advent of new
diagnostic and therapeutic strategies (1). The ﬁght against Candida albicans infections
necessitates the use of antifungal agents, and continued efforts are required to improve
the therapeutic outcomes associated with fungal infections.
Antifungal drugs that are currently available for the treatment of Candida infections
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belong to four different chemical classes and include polyenes, azoles, pyrimidine
analogues, and echinocandins (2). While polyenes and azoles target sterols and their
biosynthesis, pyrimidine analogues perturb nucleic acid biosynthesis and echinocan-
dins interfere with cell wall biosynthesis. The activity against common fungal patho-
gens and their detailed mode of action are summarized in available reviews (3, 4).
The repeated or long-term use of antifungal agents in medicine has facilitated the
development of resistance in clinically relevant species (5). When it occurs, antifungal
resistance can be a serious clinical problem due to the limited number of available
agents. In general, the incidence of antifungal resistance among human fungal patho-
gens is low to moderate, especially compared to the incidence of antibiotic resistance
among bacterial pathogens. Antifungal resistance occurrence must be considered
independently for each antifungal class and for each fungal species. Moreover, epide-
miological data regarding the incidence of resistance among fungal species are not
identically distributed worldwide (6, 7). Taken together, the small number of available
antifungal agents and the occurrence of resistance reveal the urgent need for novel
active compounds.
Natural products (NPs) have already provided a vast resource for active ingredients
in medicines. The reason for this success can be explained by the high chemical
diversity of NPs, the effects of evolutionary pressure to create biologically active
molecules, and the structural similarity of protein targets across many species (8).
In the ﬁeld of antimicrobials, NPs have met with important successes. Starting with the
discovery of penicillin, the pharmaceutical industry has relied on this source extensively
for antibiotic development. Nowadays, 80% of all available clinically used antibiotics are
directly (or indirectly) derived from NPs (9). Some antifungals, including polyenes and
echinocandins, derive directly from NPs.
The discovery of structurally novel NPs with suitable pharmacological properties as
antibiotic leads has progressed weakly in recent decades (10). Innovative strategies have
provided comprehensive proﬁles of the antifungal characteristics of given NPs and an
understanding of their mode of action for target identiﬁcation and validation (11).
In a precedent study, we reported on a strategy to identify antifungal NPs from
plant crude extracts (12). This strategy relied on the use of a C. albicans isolate highly
susceptible to growth inhibitors and in which traces of inhibitory NPs could be
detected. NPs were identiﬁed by a bioassay that could be used as a tool enabling the
rapid detection of antifungal activity. With the determination of the chemical structures
of the identiﬁed NPs, novel compounds could be readily processed for further evalu-
ation by in vivo approaches (13).
In this study, we report on a small-scale screening of selected NPs and an in-depth
characterization of their biological properties. The compounds were tested on the basis
of their activity against different pathogenic and nonpathogenic yeasts and of their
toxicity for mammalian cells. One of the promising compounds (tomatidine) showing a
high level of activity against C. albicans was further investigated. The tomatidine mode
of action was characterized in-depth for the ﬁrst time, and its activity was conﬁrmed
in vivo.
RESULTS
Screening of a small-scale library of plant NPs for antifungal activities. A library
of 199 natural products (NPs) with potential antifungal activity was built. Compounds
were selected either according to their previously reported activities or by their
structural analogy to scaffolds that were known to be active. These compounds were
obtained in two ways: either by targeted isolation from plant extracts (29 different
plants provided 53% of the investigated NPs were investigated) or by commercial
acquisition after selection on the basis of their structural similarity to documented
antifungals (see Materials and Methods; the compounds are listed in Table S1 in the
supplemental material). The 199 NPs were subjected to standard in vitro microdilution
susceptibility assays (EUCAST method) with C. albicans under acidic and neutral con-
ditions (pH 4.6 and 7.0, respectively). These different values were chosen to reﬂect the
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pHs in the different host niches of C. albicans. The results are summarized in Table 1.
When a threshold for antifungal activity of 32 g/ml was considered, our analysis
identiﬁed 33 NPs exhibiting antifungal activities. The activity threshold of 32 g/ml was
selected since we estimated that setting a high threshold for a MIC value in vitro would
be problematic when activities in vivo were tested and an attempt to achieve thera-
peutic concentration ranges in animals was made. With this threshold, while 2 com-
pounds were active at neutral pH and 18 were active only at a low pH, 13 were active
under both pH conditions (Table 1).
In order to further characterize their antifungal properties, active NPs were proﬁled
for their spectra of activity against several other clinically relevant Candida strains (C.
glabrata, C. tropicalis, C. parapsilosis, and C. krusei) as well as another related nonpatho-
genic yeast (Saccharomyces cerevisiae). As shown in Fig. 1, a variety of activity proﬁles
was observed, with some compounds being active against all strains, while others were
active against only a small subset of species, suggesting a diversity in their modes of
action and in the target cell response. C. glabrata strains (azole-sensitive [AS] and
azole-resistant [AR] strains) exhibited the most resistant phenotypes. To identify com-
TABLE 1 The 33 NPs with their biological activity proﬁles
Name No. Source
CASa registry
no.
MICb (g/ml)
LD50 by
cytotoxicity
assay
Selectivity
indexe
C. albicans
C. albicans
bioﬁlm E. colipH 7 pH 4.6
Morindone 1 Morinda tomentosa 478-29-5 32 32 6.25 64 NDd ND
Lucidine -methyl ether 2 Morinda tomentosa NAc 32 32 NA 64 ND ND
Morindoquinone 3 Morinda tomentosa New NP 32 16 25 64 100 6.25
Avocadene 4 Persea americana 24607-08-7 16 8 25 64 50 6.25
Plumbagin 5 Sigma-Aldrich 481-42-5 2 4 50 64 100 50
Alpha-hederin 6 Schefﬂera systila 27013-91-8 16 4 50 64 100 6.25
Glc-3 medicagenic acid 7 Dolichos kilimandscharicus 49792-23-6 32 2 50 64 100 100
2-Propen-1-one, 1-(2,4-dihydroxy-6-
methoxy-3,5-dimethylphenyl)-
3-phenyl
8 Myrica serrata 65349-31-7 32 8 25 64 25 3.125
O-Methyllawsone 9 Swertia calycina 2348-82-5 16 8 12.5 64 25 1.5625
Dihydrochelerythrine 10 Fagara zanthoxyloides 6880-91-7 8 32 25 64 25 3.125
Simplexene D 11 Swartzia simplex New NP 32 16 25 64 100 12.5
Waltherione G 12 Waltheria indica 1632043-42-5 32 32 25 64 ND ND
Waltherione F 13 Waltheria indica 1632043-41-4 32 8 12.5 64 50 6.25
8-Deoxoantidesmone 14 Waltheria indica NA 32 16 25 64 100 12.5
Waltherione E 15 Waltheria indica 954367-81-8 32 4 12.5 64 100 50
Pterostilbene 16 Sigma-Aldrich 537-42-8 32 32 50 64 ND ND
(5S,10S)-11,15-(S)-Dihydroxy-12-
methoxyswartziarboreol G
17 Swartzia simplex 1830306-56-3 32 16 50 64 50 3.125
Pulsatilla saponin D 18 Odontadenia puncticulosa 68027-15-6 32 16 50 64 100 6.25
3-O-[-D-Xylopyranosyl-(1¡3)]--
L-rhamnopyranosyl-(1¡2)-[-D-
glucopyranosyl- (1¡4)]--L-
arabinopyranosyl] hederagenin
19 Odontadenia puncticulosa NA 32 8 50 64 50 6.25
Garcinone C 20 Phytolab 76996-27-5 8 32 50 64 50 6.25
Pennogenin tetraglycoside 21 Phytolab 68124-04-9 4 8 50 64 6.25 1.5625
Tomatidine hydrochloride 22 Phytolab 6192-62-7 1 16 50 64 100 200
Formosanin C 23 Phytolab 50773-42-7 1 4 25 64 12.5 12.5
Medicagenic acid 24 Phytolab 599-07-5 32 2 50 64 100 100
Pyridoxatin 25 Sigma-Aldrich 135529-30-5 4 32 25 16 100 25
Isograndifoliol 26 Perovskia atriplicifolia 1445475-53-5 16 32 50 64 100 25
Taxodion 27 Salvia leriifolia 19026-31-4 16 8 12.5 64 50 3.125
Waltherione N 28 Waltheria indica New NP 32 32 12.5 64 ND ND
5-(R)-Vanessine 29 Waltheria indica New NP 32 32 12.5 64 ND ND
Waltherione Q 30 Waltheria indica New NP 32 32 25 64 ND ND
Antidesmone 31 Waltheria indica 222629-77-8 32 32 12.5 64 ND ND
Waltherione I 32 Waltheria indica 1632043-44-7 32 32 12.5 64 ND ND
Waltherione J 33 Waltheria indica 1632043-46-9 32 16 12.5 64 50 3.125
aCAS, Chemical Abstracts Service.
bThe threshold for antifungal activity was 32 g/ml.
cNA, not available.
dND, not determined.
eThe selectivity index was equal to the LD50/MIC for C. albicans.
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pounds with high antifungal potential, two major clinical antifungal agents (ﬂuconazole
and caspofungin) were added to the group of NPs selected for testing, and all clustered
according to their activity proﬁles. Four NPs (pyridoxatin, Glc-3-medicagenic acid [medica-
genic acid 3-O-glucopyranoside], medicagenic acid, plumbagin) were grouped together
with caspofungin (Fig. 1, purple highlight) and exhibited strong inhibitory activity
against all species tested. The nearest neighboring cluster contained ﬂuconazole and
included three other NPs (formosanin C, tomatidine, and taxodion; Fig. 1, red highlight).
This cluster was characterized by strong activity overall, but speciﬁc yeasts showed
reduced susceptibility to the members of this cluster, such as C. glabrata (AR) and C.
krusei strains, which showed reduced susceptibility to ﬂuconazole, and C. glabrata
strains, which showed reduced susceptibility to tomatidine.
Bioﬁlms are deﬁned as complex cell populations with intrinsic resistance to many
antifungal drugs, whereas planktonic cells of the same organism do not show such
intrinsic resistance (14). We tested the activities of selected NPs against C. albicans
mature bioﬁlms formed in vitro using an activity cutoff value higher than the one
FIG 1 Heatmap and cluster analysis of the activity proﬁles of 33 active NPs. The MIC values of the NPs against seven yeast species were ordered
by hierarchical clustering using the Euclidean distance method and are represented with a heatmap in which intensity is indicated by a color code
(dark blue, MIC of 0.125 g/ml; light blue, MIC of 32 g/ml; white, MIC of32 g/ml [inactive]). The pH at which activity was detected is indicated
by the color in the ﬁrst column (orange, pH 4.6; green, pH 7). Fluconazole and caspofungin were added to the list of compounds, and their clusters
are highlighted in red and purple, respectively.
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used for planktonic cells (MIC  50 g/ml). Most of the compounds (25 out of 33)
were active against bioﬁlms and exhibited a MIC against bioﬁlm cells higher than
the MICs measured against planktonic cells, except for NPs originating from Walthe-
ria indica. The antibioﬁlm activity of these NPs was previously reported (15).
FIG 2 Tomatidine susceptibility assays with Candida spp. (A) Structure of tomatidine. (B) Spotting susceptibility assays with Candida
spp. on YEPD agar plates. Tenfold serial dilutions of the indicated strains were spotted onto agar plates containing increasing
tomatidine concentrations (0 [DMSO], 1, 5, or 10 M tomatidine) and were incubated for 1 day at 34°C. AR, azole-resistant strain. (C)
Calcoﬂuor white staining of C. albicans cells exposed to tomatidine. Cells were exposed to 2.5M tomatidine for 3 h or left untreated
(1% DMSO) in RPMI medium (0.2% glucose) at 37°C and then labeled with calcoﬂuor white to stain the chitin. The cells depicted here
are representative of the vast majority of cells from three independent experiments. Magniﬁcations, 100. (D) Time-kill assay for
tomatidine-treated cells. C. albicans and C. krusei cells (2 105) were treated with different supra-MICs of tomatidine in YEPD, and
the numbers of CFU per milliliter were determined after 4, 8, and 24 h of exposure. The levels of growth (numbers of CFU per
milliliter) relative to the initial level (at time zero, which was considered 100%) were calculated. Experiments were performed in
duplicate, with average and SEM values being graphically represented. The y axis is on a log10 scale.
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We next tested the activity of the selected NPs (16) against a Gram-negative
bacterium (Escherichia coli). All but one compound (pyridoxatin; Table 1) were inactive
against this bacterial species (MIC  64 g/ml), arguing for fungus-speciﬁc inhibitory
activity.
The last step in the screening process was to determine the potential acute toxicity
of selected NPs on mammalian cells. The 24 most active antifungal NPs (MICs  16
g/ml) were therefore tested by standard cytotoxicity assays on HeLa cells, and the
50% lethal dose (LD50) was determined. Our results indicated that only 3 NPs, tomat-
idine, medicagenic acid, and Glc-3 medicagenic acid, showed selectivity indices (SIs)
with an acceptable range (100). The results of all the antifungal proﬁling assays are
summarized in Table 1. Since the antifungal activities of the two medicagenic acid-
based NPs have already been reported (17), we focused our efforts on understanding
the antifungal properties and mode of action of tomatidine.
Antifungal activity of tomatidine. Tomatidine (Fig. 2A) is a sterol alkaloid pro-
duced by the tomato (Solanum lycopersicum). It is the precursor of the glycol sterol
alkaloid -tomatine, which is a well-known antifungal saponin with activity against
phytopathogens (18). The antifungal and antiparasitic activities of tomatidine against S.
cerevisiae and some parasites, such as Leishmania amazonensis and Phytomonas ser-
pens, have been reported (19–21). These studies revealed that tomatidine exposure
induces a perturbation of ergosterol biosynthesis and suggested that the C-24 sterol
methyltransferase (24-SMT-Erg6) within the sterol biosynthetic pathway is a potential
target. Erg6 is responsible for the key structural difference between cholesterol and
ergosterol (21, 22). This is consistent with the fact that the ERG6 gene is present in fungi
but absent in higher eukaryotes, such as mammals. Erg6 therefore represents an
attractive target for the development of antifungal agents.
The results of tomatidine susceptibility assays with several clinically relevant Can-
dida species are shown on Fig. 2B. All strains, except C. glabrata, were highly susceptible
to tomatidine. Similar results were obtained by standard microdilution susceptibility
assays, with C. krusei and C. albicans showing the highest sensitivities (MIC 0.625 M)
(Table 2). We used a larger panel of C. albicans isolates (n  9) and found that the
tomatidine MIC50 was 0.3125 M. MIC50 values for both C. krusei (n 8) and C. tropicalis
(n  9) were 1.25 M (Table S4). Tomatidine was not active against C. albicans mature
bioﬁlms (Table 1), but the ability of C. albicans to form hyphae under ﬁlamentation-
inducing in vitro conditions was severely compromised in the presence of tomatidine.
As shown in Fig. 2C, the addition of tomatidine to C. albicans cultures under hypha-
inducing conditions resulted in the formation of pseudohyphae and/or unseparated
budding yeast cells. Tomatidine exhibited fungistatic activity against C. albicans, as
revealed by time-kill assays performed with different drug concentrations (Fig. 2D).
Tomatidine (10 M) was observed to have only weak fungicidal activity against C.
krusei, with the number of CFU being decreased by about 80% compared to that in the
starting inoculum after 24 h of incubation (Fig. 2D).
Global transcriptional analysis of tomatidine-treated C. albicans cells. Genome-
wide transcriptional analysis in the presence of given drugs has often been used as a
TABLE 2 Tomatidine and ﬂuconazole MICs for Candida spp.
Strain
MICb
RPMI (pH 7) YNB (pH 7) YPED (pH 6.5)
Tomatidine Fluconazole Tomatidine Fluconazole Tomatidine Fluconazole
C. albicans (SC5314) 0.625 0.125 0.625 0.5 1.25–2.5 0.5
C. krusei (DSY471) (ARa) 0.625 32 0.625 32 0.3125 128
C. tropicalis (DSY472) 1.25 0.25–0.5 5 128 2.5 32
C. parapsilosis (DSY473) 10 2 2.5 8 5 16
C. glabrata (DSY562) 40 2 40 32 40 64
C. glabrata (DSY562) (AR) 40 128 40 128 40 128
aAR, azole resistant.
bMICs are in micromolar for tomatidine and micrograms per milliliter for ﬂuconazole.
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means to highlight their modes of action and to propose possible cellular targets (23).
The effect of tomatidine treatments on the C. albicans transcriptome was investigated
in vitro using two different exposure times (1 and 3 h) and a ﬁxed drug concentration
(2.5 M). This drug concentration corresponds to the MIC obtained in 1% yeast extract,
2% peptone, and 2% glucose (YEPD) medium (Table 2) and led to 30% and 50% growth
inhibition after 1 h and 3 h of incubation, respectively (data not shown). Total RNA was
recovered from treated and untreated cells, and genome-wide transcriptional analysis
was performed using transcriptome sequencing (RNA-seq) (see Materials and Methods).
After 1 and 3 h of tomatidine exposure, 129 and 1,149 genes (2% and 21% of the genes
expressed by treated and untreated cells, respectively) were identiﬁed to be differen-
tially expressed between treated and untreated cells (false discovery rate [FDR], 0.05;
fold change, 2), respectively. One hundred twelve genes were found to be affected
after both 1 and 3 h of exposure. Seventy-seven genes were upregulated, 32 genes
were downregulated, and 3 genes were inversely regulated compared to their regula-
tion under untreated conditions (Fig. 3A; Data Set S1). Gene Ontology (GO) term
analysis of the 77 commonly upregulated genes revealed a clear alteration of the
expression of 6 genes (ERG2, ERG3, ERG4, ERG6, ERG11, ERG25) involved in the ergosterol
biosynthetic pathway (corrected P value  0.0004) (Fig. 3B). Interestingly, other com-
ponents of the ergosterol biosynthetic pathway were found to be upregulated by
tomatidine after 1 h of exposure, including ERG1, ERG5, ERG24, and UPC2 (the master
sterol transcriptional regulator), and 3 h of exposure, including ERG9 and ERG28 (Data
Set S1). Interestingly, among all the ERG genes differentially regulated by tomatidine
exposure, the most affected was ERG6, which showed 7.4- and 11.8-fold changes in the
level of expression after 1 and 3 h of treatment, respectively. This important fold change
in expression was conﬁrmed by quantitative PCR (qPCR) analysis (up to a 40-fold
increase at 3 h of treatment) (Fig. 3C).
Response to steroid hormone stimulus was another overrepresented GO term
among the upregulated genes (corrected P value  0.002). The three corresponding
genes were part of the TAC1 regulon and are involved in the major drug efﬂux system
in C. albicans: the two ABC transporters (CDR1 and CDR2) and the transcriptional
regulator itself (TAC1) (Fig. 3B). qPCR analysis of ERG4, ERG6, ERG11, CDR1, and CDR2
expression from the same RNA samples validated the results of RNA-seq data analysis
(Fig. 3C and S1).
GO analysis identiﬁed only one enriched GO term (ion transport; corrected P value 
0.003) for commonly downregulated genes (32 genes), with 2 genes being involved in iron
or calcium transport (FET34, FTR1).
Exposure of C. albicans cells to tomatidine for 3 h led to large transcriptional
changes (in a total of 1,149 genes), with 1,037 genes speciﬁcally being affected after
that exposure time. GO term analysis identiﬁed processes that are characteristics of
growth inhibition/arrest or drug-related stress, such as glucose transport in upregu-
lated genes and the transcriptional and translational machinery in downregulated
genes (Data Set S1).
In order to better characterize the response to tomatidine, we used gene set
enrichment analysis (GSEA) to identify transcriptional signatures from other drug-
induced transcriptional studies overlapping the present tomatidine transcriptional data
(Data Set S2). As shown in Fig. 3D, genes up- and downregulated by tomatidine (red
and blue, respectively) shared the highest number of regulated genes with the ﬂu-
conazole_UP/DOWN gene sets, followed by another azole-related gene set (ketocona-
zole_UP/DOWN) and the gene set from cells lacking the master regulator of ergosterol
genes (UPC2). Using another set of previously published transcriptional data obtained
under several growth conditions inducing stress in vitro (such as hypoxia [24]), the set
of genes regulated under tomatidine treatment conditions shared genes regulated
under hypoxic conditions, in which the adaptive response is mainly mediated by UPC2
(Fig. S2) (25). Taken together, these analyses reveal that tomatidine has a transcriptional
signature closely related to that of azole drugs and strongly suggest that the ergosterol
biosynthetic pathway is also targeted by this NP.
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Tomatidine as an inhibitor of the sterol biosynthetic pathway. As suggested by
the results of our transcriptional analysis, tomatidine is likely to interfere with ergosterol
biosynthesis, given that the upregulation of ERG genes upon treatment has been
shown to be a mechanism in the cell involved in the response to drugs targeting
the ergosterol pathway (26). In order to detect more precisely the step(s) of this
pathway that was affected, we performed an in-depth analysis of the sterol content
of C. albicans, C. krusei, and S. cerevisiae cells treated with tomatidine. Total sterols were
extracted from yeast cells and next subjected to gas-liquid chromatography coupled
with mass spectrometry (GLC-MS) analysis.
As shown in Fig. 4A, untreated C. albicans cells contained, as expected, ergosterol as
the most abundant sterol (96% of total sterols). Zymosterol (the product known to
A
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cells. The increase in the fold change in expression compared to the level of expression in untreated cells is represented as a bar plot. A t test analysis of the
relative level of gene expression between the treated and untreated groups was performed for each gene, and signiﬁcant differences were detected (P values
for all comparison,0.05). (D) Gene set enrichment analysis (GSEA) of C. albicans genes regulated by tomatidine. The list of drug-regulated genes was generated
from published transcriptional data (see Data Set S2 in the supplemental material; data ﬁle name, Candida_drug_treatment.gmt). Tomatidine-regulated genes
(3 h) are ranked according to their fold change in expression. The list was then imported into GSEA software. Analysis parameters were as follows:
normalization mode (norm), meandiv; scoring scheme parameter, weighted; minimal gene set size, 15; number of permutations, 1,000; maximal gene set size,
500. GSEA results were uploaded into Cytoscape (version 3.0) software with the following parameters: P value cutoff, 0.01; FDR q value, 0.05. Red nodes, enriched
genes among upregulated genes from GSEA; blue nodes, enriched genes among downregulated genes from GSEA. Nodes (colored circles) are connected by
edges (connecting lines) when overlaps exist between nodes. The size of the nodes reﬂects the total number of genes that are connected by edges to
neighboring nodes. The labels of the list (corresponding to the list of genes upregulated [UP] and downregulated [DOWN] by drug treatments, gene deletions,
or stress conditions) are indicated next to the nodes (see Data Set S2 for details). XSA and XSB, oxidative shock; HU6H, hydroxyurea treatment.
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accumulate in the ERG6 [encoding C-24 sterol methyltransferase] mutant) was the
major sterol (84% of total sterols) in tomatidine-treated cells, thus suggesting strong
inhibition of this enzymatic step by tomatidine. Furthermore, careful analysis of the
sterol content allowed the identiﬁcation of a small amount of two other sterol inter-
mediates, including cholesta-trienol (6%) and ergosta-5,7,24(28)-tetraenol (8%). En-
zymes involved in the late stage of ergosterol biosynthesis usually act independently of
each other, which enables the pathway to proceed even if one step is inhibited by a
drug or is genetically suppressed, leading to the synthesis of alternative sterols. One of
those is cholesta-trienol, which was detected in tomatidine-inhibited cells, where the
successive actions of Erg2, Erg3, and Erg5 occurred in the absence of previous Erg6
activity. However, Erg4, the last enzyme involved in the sterol pathway, ﬁrst requires the
action of Erg6 to produce its substrate. More speciﬁcally, the methylene group added
by Erg6 at position C-24 of zymosterol is the substrate for the C-24 reductase activity
of Erg4. Therefore, detection of the Erg4 substrate [ergosta-5,7,24(28)-tetraenol] was
unanticipated and suggested that (i) tomatidine also inhibited Erg4 and (ii) Erg6 was
not completely inhibited by tomatidine at the concentration tested.
In order to be able to assess more accurately the inhibition of Erg4 activity, we next
performed a progressive decrease of Erg6 inhibition by titrating down the tomatidine
concentration. As shown in Fig. 4A, a decrease in the tomatidine concentration from 2
M to 0.25 M resulted in the release of Erg6 inhibition (the amount of zymosterol as
a proportion of total sterols decreased from 84% to 7%) and the accumulation of
FIG 4 Analysis of total sterols in tomatidine-treated cells by GLC-MS. (A) Sterol composition of C. albicans cells
treated with increasing amounts of tomatidine. (Left) The results of GLC-MS analysis of cells exposed to tomatidine
indicate the percentages of the different sterols in a bar plot. The bar colors correspond to those of the sterol
molecules illustrated on the right, where the last steps in the ergosterol biosynthetic pathway and an alternative
pathway following ERG6 inhibition are shown. The experiment was repeated in duplicate and gave similar results
each time. (B) Assay of the susceptibility of the C. albicans ERG6 deletion strain. Wild-type (ERG6/ERG6), heterozy-
gous (ERG6/erg6Δ), or homozygous ERG6 (erg6Δ/erg6Δ) deletion strains were subjected to a serial dilution
susceptibility assay on YEPD plates containing the indicated concentration of tomatidine or ﬂuconazole (left) and
to standard MIC determination assay in YNB (pH 7) medium (right).
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ergosta-5,7,24(28)-tetraenol (which consisted of up to 72% of total sterols with 0.25 M
tomatidine), thus conﬁrming the ability of tomatidine to inhibit Erg4. As the concentration
of tomatidine required to accumulate zymosterol and ergosta-5,7,24(28)-tetraenol as a
proportion of total sterols of up to 84% and 72%, respectively, is approximately 2 M
and 0.25 M, respectively, one can estimate that tomatidine is about 10 times more
effective as an inhibitor of Erg4 than as an inhibitor of Erg6. Interestingly, this Erg4/Erg6
dual inhibition was also found in C. krusei but not in S. cerevisiae, in which only Erg6
inhibition could be detected (Fig. S3).
Following this analysis, a C. albicans ERG6 deletion strain was engineered in order to
validate that Erg6 is a target of tomatidine. We reasoned that if the Erg6 target is
absent, then tomatidine will not be active against this mutant. As already described, the
deletion of ERG6 results in increased susceptibility to a large variety of drugs, with the
exception of azoles and polyenes (27). The erg6Δ/erg6Δ mutant was indeed resistant to
ﬂuconazole, with the MIC for the mutant being 128-fold higher than that for the wild
type (Fig. 4B). Interestingly, the erg6Δ/erg6Δ mutant constructed here was as suscep-
tible to tomatidine as the parental strain (Fig. 4B). This indicates a pleiotropic suscep-
tibility of the strain or a potential secondary target(s) of tomatidine, in addition to the
ergosterol pathway. Similar results were obtained using an S. cerevisiae ERG6 mutant
(Fig. S4).
Use of a forward genetic approach to identify targets of tomatidine. A forward
genetic screen in S. cerevisiae was ﬁnally undertaken as an unbiased way to discover the
target(s) of tomatidine. The strain chosen in this approach lacked PDR5 and MSH2 to
avoid multidrug transporter-dependent resistance mechanisms and to increase the
rates at which resistance mutations may occur, respectively (28, 29). A pdr5Δ msh2Δ
strain (strain P1) was plated on YEPD medium containing 10 M tomatidine, and after
a screening of more than 2  108 cells, one resistant mutant (mutant R1) was isolated.
To obtain additional resistant mutants, a second strategy inspired by Ojini and Gammie
(29) was developed and consisted of submitting cells to two drug exposure periods in
liquid medium (72 and 48 h) interspersed by a period of drug-free growth (48 h).
Cultures with robust growth at the end of the experiment were further plated on solid
YEPD medium containing 10 M tomatidine, which resulted in the isolation of four
resistant mutants (mutants R2, R3.1, R3.2, and R3.4) from two different cultures.
The tomatidine resistance of the ﬁve mutants obtained was conﬁrmed by a serial
dilution assay (Fig. 5A). MIC results showed a 4-fold decrease in susceptibility for R1,
R3.1, and R3.2 compared to that of parental strain P1. Isolates R3.3 and R2 exhibited
only a slight decrease in susceptibility. Tomatidine resistance was speciﬁc, since the
results of susceptibility assays with drugs of different classes (ﬂuconazole, caspofungin,
and amphotericin B) showed that the MICs of ﬂuconazole, caspofungin, and ampho-
tericin B for the mutant strains were in the range of those for strain P1 (Table 3).
Simpliﬁed sterol composition analysis using the unique spectrophotometric absor-
bance signature of sterols conﬁrmed that the mutants had a normal sterol composition
with no detectable differences from that of the parental strain (Fig. S5A).
The ﬁve mutant genomes were sequenced, and the sequences were compared with
the sequence of parental strain P1. Alignment of the sequences of the parental and
mutant genomes with the sequence of the reference genome (S288C) was followed by
the identiﬁcation of nonsynonymous polymorphisms uniquely present in the coding
regions of the resistant mutants (see Materials and Methods). All the nonsynonymous
mutations inventoried in the ﬁve resistant mutants (between 26 and 60, depending on
the strain) are listed in Data Set S3. Interestingly, four out of the ﬁve resistant mutants
contained a missense mutation in ERG6 with the following amino acid substitutions:
D249G for R1, R3.1, and R3.2 and G132D for R2. These amino acid residues might play
an important role in Erg6 function, as they are conserved among fungi, plants, and
protozoa (30) (Fig. 5B), but they seemed dispensable for normal ergosterol synthesis. To
determine if the two mutations were sufﬁcient to confer tomatidine resistance, the
G132D and D249G substitutions were inserted in a wild-type S. cerevisiae strain
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(IMX585) using the site-directed clustered regularly interspaced short palindromic
repeat (CRISPR)-Cas9 genome editing technology (31). Both strains (the G132D and
D249G mutants) were 4-fold more resistant to tomatidine than the wild type (Table 3),
thus recapitulating the tomatidine-resistant phenotype of the original resistant mutants
(or, for the G132D mutant, increasing its level of resistance). Analysis of the sterol
proﬁles showed that the G132D strain, in contrast to the corresponding original resistant
mutant and the D249G strain, exhibited an altered sterol composition with proﬁles
S. cerevisiae
C. albicans
P. carinii
T. brucei
G. zeae
A. thaliana
G. max
S. cerevisiae
C. albicans
P. carinii
T. brucei
G. zeae
A. thaliana
G. max
S. cerevisiae
C. albicans
P. carinii
T. brucei
G. zeae
A. thaliana
G. max
S. cerevisiae
C. albicans
P. carinii
T. brucei
G. zeae
A. thaliana
G. max
S. cerevisiae
C. albicans
P. carinii
T. brucei
G. zeae
A. thaliana
G. max
Parental P1
R2
R3.1
R3.2
R3.3
R1
A
B Sterol methyltransferase (SMT-Erg6)
G132D: R2 D249G: R1, R3.1, R3.2
Ø 1 μM 5 μM 10 μM
Tomatidine
FIG 5 Forward genetic approach in S. cerevisiae. (A) Tomatidine susceptibility of resistant mutants. Fungal cells were spotted on YEPD agar containing different
concentrations of tomatidine (and a drug-free control), as indicated. The plates were incubated at 30°C for 48 h. (B) Alignment of the C-24 sterol
methyltransferase (SMT) protein sequences from distant eukaryotic species (fungi, S. cerevisiae, C. albicans, Pneumocystis carinii, and Giberella zeae; green plants,
Glycine max and Arabidopsis thaliana; euglenozoan, Trypanosoma brucei). Gray, conserved residues; black boxes, highly conserved regions that have a role in
substrate binding and enzymatic activity (30); red boxes, the two mutated residues found in C-24 sterol methyltransferase (Erg6) of tomatidine-resistant strains
(G132D and D249G) conserved across all aligned sequences. Strains carrying the ERG6 mutation are indicated below the alignment. The GenBank accession
numbers of the protein sequences are as follows: S. cerevisiae, KZV08836; C. albicans, AOW28252; P. carinii, KTW25893; G. zeae, ESU10532; G. max, NP_001238391;
A. thaliana, NP_173458; and T. brucei, AAZ40214. A multiple-sequence alignment was performed using the MUSCLE program in Geneious software (version 9.1.4;
default parameters).
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intermediate between those of an ERG6 deletion mutant and a wild-type strain (Fig.
S5B). This might explain the increase in ﬂuconazole susceptibility observed for this
strain (Table 3).
While the last resistant mutant (mutant R3.3) retained a wild-type allele of ERG6, it
exhibited a frameshift mutation in ACE2. This gene encodes a transcription factor
required for septum degradation after cytokinesis (32). Strain R3.3 exhibited a multi-
cellular clumping phenotype, which was identical to that of an ACE2 deletion strain (Fig.
S6). A decrease in tomatidine susceptibility was observed in the ACE2 deletion strain
and thus recapitulated the resistance phenotype of the initial R3.3 strain (Table 3).
Tomatidine is targeted by efﬂux pumps. The forward genetic approach was
designed to exclude multidrug transporter-dependent resistance mechanisms by using
an S. cerevisiae strain lacking PDR5. However, the activation of drug efﬂux in yeast is a
common cell defense mechanism against toxic drugs, as observed in our C. albicans
genome-wide transcriptional analysis, in which the genes of the TAC1 regulon (includ-
ing CDR1 and CDR2) were among the genes upregulated by exposure to tomatidine
(Fig. 3B). To address whether tomatidine was a target of the efﬂux pump system in C.
albicans, a set of deletion mutants lacking CDR1, CDR2, or MDR1 (another import efﬂux
pump belonging to the major facilitator superfamily of transporters) was used to
evaluate their tomatidine susceptibility. The cdr1Δ/cdr1Δ strain was the only one to
exhibit increased susceptibility to tomatidine; the CDR2 and MDR1 mutants and the
wild-type strain did not (Fig. 6A). These data clearly indicate that, like many other drugs,
such as ﬂuconazole (33), tomatidine is targeted by the CDR1 efﬂux pump.
A major problem arising during clinical treatment of candidiasis is the emergence of
resistant isolates. One important mechanism underlying the development of resistance
consists of the upregulation of efﬂux pumps by the acquisition of hyperactive alleles of
their regulators (16). To evaluate the potential cross-resistance between ﬂuconazole
and tomatidine of strains with hyperactive TAC1 alleles, we measured the tomatidine
susceptibility of two pairs of matched azole-susceptible (AS) and azole-resistant (AR) C.
albicans clinical isolates. The AR isolates carried hyperactive TAC1 alleles. While the
difference in the ﬂuconazole MIC between strains DSY732 (AR) and DSY731 (AS) was
64-fold, the tomatidine MIC diverged by only 4-fold between the two strains (Fig. 6B,
left; Table 4). Similar results were obtained using C. albicans clinical isolates DSY1843
(AR) and DSY1841 (AS). Azole and tomatidine MICs increased by only 4- and 2-fold,
respectively (Fig. 6B, right; Table 4). Taken together, these results suggest that the
common mechanism of resistance to azoles triggered by TAC1 hyperactivity seems to
have a limited effect on tomatidine susceptibility.
As C. albicans exhibited limited cross-resistance between ﬂuconazole and tomati-
dine, we next investigated the potential synergistic effect of their combination. Classical
checkerboard combination assays were performed, and fractional inhibitory concen-
tration (FIC) values were determined (as described in Materials and Methods). As
expected for drugs targeting the same pathway, ﬂuconazole and tomatidine exhibited
TABLE 3MICs of different antifungals for S. cerevisiae strains
Strain
MICa
Tomatidine Fluconazole Caspofungin Amphotericin B
P1 1.25 4 0.25 2
R2 1.25 4 0.25 2
R3.1 5 4 0.25 2
R3.2 5 4 0.25 2
R3.3 2.5 4 0.25 2
R1 5 4 0.25 2
IMX581 5 16 0.125 2
D249G 20 16 0.125 2
G132D 20 4 0.125 2
aMICs are in micromolar for tomatidine and micrograms per milliliter for ﬂuconazole, caspofungin, and
amphotericin B.
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FIG 6 Tomatidine targets efﬂux pumps and induces only partial cross-resistance with ﬂuconazole. (A) Serial dilution susceptibility assays of C. albicans strains
carrying a deletion of efﬂux pump genes (the genotypes are indicated) on YEPD agar plates. Tenfold serial dilutions of the indicated strains were spotted onto
agar plates containing increasing tomatidine concentrations (0, 0.5, 1, 5 M) and were incubated for 1 day at 34°C. (B) Tomatidine MICs of two matched pairs
of azole-susceptible (AS) and azole-resistant (AR) strains. Determination of the MICs of tomatidine and ﬂuconazole was performed in YNB medium, and the MICs
(Continued on next page)
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a strong additive effect in both C. albicans and C. krusei, with cell growth inhibition by
the two drugs in combination being more than 50%, which is in the zone of additivity
(Fig. 6C). We then tested if the combination of the two drugs changed their fungistatic
properties. Interestingly, a time-kill assay showed that use of the ﬂuconazole-
tomatidine combination led to fungicidal activity against C. krusei (a 100-fold de-
crease in cells counts after 24 h) but not against C. albicans (Fig. 6D).
In vivo activity of tomatidine. To conﬁrm the strong potential for tomatidine to be
a therapeutic agent, the in vivo efﬁcacy of the compound was tested in a mouse model
of C. albicans systemic infection. Due to its hydrophobic nature, a nanoparticle-based
formulation of tomatidine was developed to allow its administration and to potentially
enhance its bioavailability. Mice were infected through the tail vein with a C. albicans
inoculum and were treated intraperitoneally (i.p.) with tomatidine (50 mg/kg of body
weight) or placebo at 6 h, 24 h, and 31 h postinfection (p.i.). The numbers of CFU in the
kidneys were then determined at 48 h p.i. As illustrated in Fig. 7, mice treated with
tomatidine exhibited statistically signiﬁcantly reduced numbers of CFU compared to
the controls (Mann-Whitney test, P  0.031), thus highlighting the in vivo activity of
tomatidine and its therapeutic potential.
DISCUSSION
NPs as sources of antifungal agents. The aim of our study was to identify
promising natural compounds with antifungal activity, starting with a small-scale
screening of carefully selected compounds, proceeding with an extensive in vitro
characterization of their antifungal properties and cytotoxicity, and then extending to
the identiﬁcation of their cellular targets and the validation of their in vivo therapeutic
potential.
A library of 199 natural products was built using both direct isolation from extracts
of plants with documented antifungal properties (29 different plants were investigated,
and 53% of the NPs investigated were isolated from these plants) and commercial
acquisition after selection on the basis of structural similarities with known antifungals.
The efﬁciency of the preselection process explains the high positive hit rate (17%;
33/199) of NPs with activity against human pathogens when a cutoff MIC value of 32
g/ml was used. From an extended bioactivity proﬁling procedure, including assays on
different fungal strains, a bacterial strain, and cytotoxicity assays for therapeutic index
evaluation, only three interesting leads were identiﬁed. Tomatidine stood out as a novel
anti-Candida drug with a putative promising target.
FIG 6 Legend (Continued)
are indicated by the arrows. Δ, difference in the fold change in the MICs between matched AS and AR strains. (C) Two heatmaps representing color plots of
the results of checkerboard MIC tests. Each box corresponds to the relative growth (compared to that of the drug-free control) resulting from a speciﬁc
combination of tomatidine and ﬂuconazole (RPMI medium, pH 7). The MIC of each drug is underlined. Zones with a black border, additive interaction (FIC index,
between 2 and 0.5); zones with a yellow border, synergistic effect (FIC, 0.5). (D) Time-kill assay of C. albicans and C. krusei cells exposed to a combination of
tomatidine (T) and ﬂuconazole (F). Cells were treated with the indicated amounts of the drugs, individually or in combination, in YEPD medium; the number
of CFU per milliliter was determined after 4, 8, and 24 h of exposure; and the number of CFU relative to that at time zero (for which the number of CFU was
considered 100%) was calculated. Experiments were performed in duplicate, with average and SEM values being graphically represented. The y axes are on a
log10 scale. On the graph for C. krusei, a dashed line was plotted at y equal to 1 to delimit the fungicidal threshold (2 times a log10 decrease).
TABLE 4 Susceptibility of C. albicans clinical isolates to tomatidine and ﬂuconazole
Straina
MICb
Tomatidine Fluconazole
DSY731 (AS) 0.625 1
DSY732 (AR) 2.5 64
DSY1841 (AS) 2.5 8
DSY1843 (AR) 5 32
aAR, azole resistant; AS, azole susceptible.
bMICs were determined in YNB (pH 7) and are in micromolar for tomatidine and micrograms per milliliter for
ﬂuconazole.
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Tomatidine is a sterol alkaloid from tomato plants with a cholesterol-derived hy-
drophobic 27-carbon skeleton and serves as a precursor intermediate in the synthesis
of a plant defense metabolite, the glycol sterol alkaloid -tomatine (34). The latter has
been characterized as an antifungal agent with activity against a large variety of phyto-
pathogens and possesses membrane disruption properties (unspeciﬁc toxicity), caused by
its ability to form complexes with cholesterol and ergosterol (18, 35). -Tomatine is present
in most green parts of tomato plants, where it is subjected to degradation during matu-
ration. In contrast, tomatidine, the aglycone of -tomatine, has a different mode of action,
as it does not show any sterol binding activity (35). It is poorly active against phytopatho-
gens, it exhibits no toxicity in vivo, and it is present in only trace amounts in the tomato
plant (18, 19, 36). Tomatidine has been reported to have antifungal and antiparasitic
activity against S. cerevisiae and Leishmania amazonensis (19, 20), and a putative target,
the C-24 sterol methyltransferase (24-SMT-Erg6) was proposed. In the present study,
the antifungal activity of tomatidine against important fungal pathogens was charac-
terized in-depth for the ﬁrst time. All Candida spp. except C. glabrata were susceptible
to tomatidine (MIC  0.25 to 10 M; Table 2).
Tomatidine mode of action. Multilevel investigations were then conducted in
order to determine its mode of action and to identify its molecular target. A ﬁrst
genomic strategy characterized a tomatidine-speciﬁc transcriptional signature in C.
albicans and identiﬁed an important upregulation of the ergosterol biosynthetic genes,
including ERG6, which was the most affected gene (Fig. 3). These results conﬁrmed the
ﬁndings of published studies of S. cerevisiae (19) and pointed out that the ergosterol
pathway is the target of tomatidine. Interestingly, GSEA identiﬁed ﬂuconazole to be a
FIG 7 In vivo efﬁcacy of tomatidine in a mouse model of systemic infection. (A) Schematic representation of the infection and
treatment protocol. Mice were infected with 4  105 CFU through the tail vein. Tomatidine treatment (50 mg/kg) (or placebo)
was administered intraperitoneally at 7, 24, and 31 h postinfection (p.i.). At 48 h p.i., animals were sacriﬁced and kidneys were
collected for determination of the number of CFU. (B) Fungal burden in tomatidine-treated mice. The number of CFU per gram
of kidney is plotted for placebo- and tomatidine-treated mice. Signiﬁcant differences in the distribution of the number of CFU
were assessed using the Mann-Whitney test (n  9 and 10 for the tomatidine- and placebo-treated mice, respectively; P 
0.031).
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mediator of the transcriptional signature most closely related to that mediated by
tomatidine (Fig. 3), which is consistent with their inhibitory activities being directed to
the same pathway. Furthermore, this convergence of azole and tomatidine activity
was also shown by microscopic analysis of the cytological effect of the drugs on the
ultrastructure of C. albicans cells (see Fig. S7 in the supplemental material).
Considering the ﬁndings presented above, a detailed analysis of the sterols in C.
albicans and C. krusei using GLC-MS resulted in the indirect identiﬁcation of (i) Erg6
inhibition through a high level of accumulation of the Erg6 substrate zymosterol in cells
treated with a high concentration of tomatidine and (ii) Erg4 inhibition through a high
level of accumulation of ergosta-5,7,24(28)-tetraenol, its substrate, in cells treated with
a low concentration of tomatidine (Fig. 4). As Erg4 needs Erg6 activity to obtain its
substrate, the identiﬁcation of this dual Erg4-Erg6 inhibition was made possible by the
likely higher afﬁnity of tomatidine for Erg4 than for Erg6. Both enzymes target the C-24
position in the ergosterol precursor and thereby probably exhibit a similar binding
pocket conformation, even if their protein sequence identity is low (15%). A dual effect
on Erg4 and Erg6 had already been reported in S. cerevisiae for azasterol, a sterol
carrying a nitrogen in the side chain (37), and thus reinforces the idea of structural
similarities between the targets. Dual inhibition by tomatidine was not detected in S.
cerevisiae, where no ergosta-5,7,24(28)-tetraenol was identiﬁed, even at a low concen-
tration. This suggests that either Erg4 in S. cerevisiae is not inhibited by tomatidine or
it has a lower afﬁnity for tomatidine than Erg6 does. These intraspecies differences
could be attributed to Erg4-independent genetic evolution, as single point mutations
in ERG6 can affect sensitivity to tomatidine.
It has been shown that deletion of the target of ﬂuconazole (ERG11) in C. albicans
caused a marked increase in its resistance to the drug (38). We applied the same paradigm
to tomatidine and tested the susceptibility of an ERG6 deletion strain. Late-acting ergosterol
genes are not essential for cell viability, and ergosterol is replaced by altered sterols in the
membrane of deletion strains (39). However, these substitutions impact the regulation of
membrane permeability and ﬂuidity and are associated with diverse phenotypic alter-
ations. A yeast ERG6 deletion mutant showed pleiotropic hypersensitivity to a broad
range of antifungal compounds and metabolic inhibitors, reﬂecting increased mem-
brane permeability and passive diffusion by small molecules (mostly hydrophobic) (27,
39, 40). The fact that the tomatidine susceptibility of the C. albicans ERG6 deletion strain
was similar to that of the wild-type strain was intriguing. It is known that ERG6 deletion
can alter the permeability of the cell membrane to different drugs, and this phenotype
has been utilized by others in order to improve the effects of different drugs (41). Given
that ERG6 deletion results in a slightly increased susceptibility to tomatidine compared
to that of the wild type, it suggests that the compound could still target other cellular
components. Consistent with this hypothesis, we identiﬁed ACE2 to be another putative
target of tomatidine (see below). It is interesting to note that the C. albicans ERG6
deletion strain was resistant to ﬂuconazole (Fig. 4B), which indicates drug-dependent
susceptibility phenotypes and thus excludes the possibility of an unspeciﬁc hypersen-
sitivity response to a given stressor.
The aim of our use of a forward genetic approach in S. cerevisiae was to identify
alternative targets of tomatidine by avoiding the interference of efﬂux pump hyper-
activity mechanisms. However, our screen revealed Erg6 to be a major target, and
several explanations can be proposed for this. First, the set of resistant mutants that we
obtained was relatively small (5), thus limiting the ability to discover additional targets.
Second, an alternative target could be accessible or present only in an ERG6 deletion
background, in which altered sterols with compromised cell membrane functions are
present. The hypothesis of a pleiotropic effect of the ERG6 deletion on susceptibility to
small hydrophobic molecules was tested using a sterol alkaloid (solasodine) which
possesses a chemical structure highly similar to that of tomatidine (they differ only in
the planar conﬁguration of the piperidine ring and an unsaturated alpha ring bond).
While this molecule was inactive against a C. albicans wild-type strain (MIC  40 M),
the deletion of ERG6 increased drug susceptibility (MIC  20 M) and thus argued for
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an unspeciﬁc drug hypersensitivity of this strain. Furthermore, in vitro ﬁlamentation
studies with C. albicans (Fig. 2D) attested to the similar pseudohyphae and/or unsepa-
rated budding yeast cell phenotype between tomatidine-treated wild-type cells and
cells depleted of ERG6, arguing for the possibility that tomatidine has a major target.
The forward genetic approach identiﬁed ACE2 to be a possible tomatidine target.
Interestingly, ACE2 deletion in C. albicans results in the upregulation of several ERG
genes involved in sterol biosynthesis (42), and thus, we reasoned that ERG6 could be
upregulated in resistant mutant R3.3, thus resulting in tomatidine resistance. ERG6
expression was, however, not signiﬁcantly altered in R3.3 compared to that in the
parent, and thus, the basis of resistance by ACE2 remains unresolved.
In comparison to previous reports from studies with S. cerevisiae that suggest that
Erg6 is a tomatidine target (19), our forward genetic approach evidenced a direct
interaction between Erg6 and tomatidine, with a single substitution of well-conserved
amino acids (G132D or D249G) being sufﬁcient to confer resistance. As a loss of
function in Erg6 results in increased susceptibility to tomatidine, the two mutations
did not drastically affect Erg6 function (ergosterol was detected, and amphotericin
B susceptibility remained unaffected). In the absence of an X-ray structure for C-24
sterol methyltransferase (Erg6), a previous functional analysis using bioinformatics
analysis, mechanism-based inactivation, and site-directed mutagenesis experiments
identiﬁed functionally important residues in three regions (Fig. 5B) (30). The two
residues (G132D and D249G) were not included in these analyses, and their effect
on the kinetics of the C-methylation reaction remains to be determined. To address
the mechanism of Erg6 inhibition by tomatidine, studies of a known Erg6 inhibitor,
25-azalanosterol, have suggested noncompetitive binding to a site different from the
sterol binding site in the active center which leads to conformational changes delete-
rious to the catalytic reaction (30, 43). The two identiﬁed residues could mediate direct
interactions with tomatidine, and nonconserved changes in these positions may result
in a decreased afﬁnity to the drug.
An important issue concerning the potential of tomatidine as an antifungal drug is
its resilience to efﬂux pump-mediated mechanisms, which are commonly acquired by
azole exposure. We showed here that tomatidine is the substrate of Cdr1 in C. albicans.
By extrapolation, we can hypothesize that the absence of activity against C. glabrata,
which is known to possess intrinsic resistance to antifungals, is related to its potent
efﬂux machinery. Nevertheless, we showed, using matched azole-sensitive and azole-
resistant clinical isolates, that the common mechanism of resistance to azole through
TAC1 hyperactivity had a limited effect on tomatidine susceptibility. This reduced
cross-resistance and the increased ﬂuconazole susceptibility of a tomatidine-resistant
strain (via G132D) raised the question about the potential therapeutic advantage of the
combined use of the two drugs. Our analysis revealed an additive effect of the
combination against a wild-type strain of C. albicans. In a recent study (44), a screen for
molecules with synergistic activity when they are used in combination with ﬂuconazole
against a C. albicans azole-resistant strain (with ERG11 and TAC1 mutations) identiﬁed
a synergistic interaction with tomatidine, thus conﬁrming the strong potential for the
use of tomatidine in drug combination therapies.
In vivo activity of tomatidine. Our initial choice to screen a library of NPs was
guided by the intrinsic properties of these natural compounds compared to those of
synthetic products, namely, their immense chemical diversity, target speciﬁcity, and
intrinsic ability to permeate cells. The critical step in the development of new antifungal
agents is to validate promising in vitro characteristics in vivo, and by choosing NPs, we
were hoping to bypass this bottleneck. In vivo studies have validated that the target of
tomatidine (Erg6) is required for virulence in both mice and insect minihost models of
C. albicans systemic infection (45; data not shown). Tomatidine is a highly hydrophobic
sterol-like molecule difﬁcult to dissolve using common aqueous solvents. First attempts
to demonstrate the in vivo activity of tomatidine in an animal model of C. albicans
systemic infection using (co)solvents (dimethyl sulfoxide [DMSO], ethanol) or cyclodex-
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trin complexation (hydroxypropyl beta-cyclodextrin) or surfactant (polyoxyl 35 castor
oil) were not successful. We next reasoned that other types of drug formulations could
be more successful. Several studies have used nanoparticle preparations to increase
drug efﬁcacy in vivo. For example, Moazeni et al. (46) have reverted the in vitro azole
resistance of Candida spp. with solid lipid nanoparticles prepared with ﬂuconazole.
Inspired by this work, we prepared a nanoparticle-based tomatidine formulation. This
formulation, which did not affect the in vitro activity of tomatidine and did not modify
its chemical structure, was injected i.p. and signiﬁcantly decreased the fungal burden
in the kidney compared to that achieved with placebo. Further studies are necessary to
understand the bioavailability and biodistribution of tomatidine in mice; however, our
work clearly raises the possibility that tomatidine is a novel potential therapeutic
antifungal agent.
MATERIALS AND METHODS
Yeast strains, culture, and growth media. The yeast and bacterial strains used in the study are
listed in Table S1 in the supplemental material. NPs were dissolved in DMSO to 10 g/ml. Tomatidine
(tomatidine-HCl) was purchased from Phytolab (GmbH), dissolved in DMSO at a 2 mM concentration,
heated for 20 min at 50°C for solubilization, and stored at 20°C until usage.
Antimicrobial susceptibility testing. (i) Antifungal broth microdilution assays. Antifungal sus-
ceptibility testing was carried out on the basis of EUCAST protocols with slight modiﬁcations (47). Brieﬂy,
yeast strains were cultivated overnight at 30°C under constant agitation in 1% yeast extract, 2% peptone,
and 2% glucose (YEPD) medium. Cultures were diluted to a density of 2  105 cells per ml in RPMI
medium (catalog number R8755; Sigma-Aldrich) or yeast nitrogen base (YNB; MPbio, Santa Ana, CA, USA)
that was buffered to an adequate pH with HCl or NaOH and that had a ﬁnal glucose concentration of 2%.
Compounds from the NP library were dissolved to a ﬁnal concentration of 10 mg/ml in DMSO. The ﬁnal
DMSO concentration was 1%. Twofold serial dilutions with concentrations ranging from 32 to 1 g/ml
were prepared. The plates were incubated at 35°C for 24 h, and then the MICs were read with a
spectrophotometer plate reader set at 450 nm. The MIC was deﬁned as the drug concentration at which
the optical density (OD) was equal to or decreased by more than 50% from that of the drug-free culture.
For S. cerevisiae MICs, the medium (YNB) was complemented with complete supplement mixture (CSM;
Mpbio, Santa Ana, CA, USA) according to the supplier’s instructions. Assays were performed in triplicate.
For the detection of an effect of the combination of tomatidine and ﬂuconazole, a checkerboard
assay was set up in YNB (pH 7) with 2-fold dilutions of ﬂuconazole (0.008 to 0.5 g/ml, 1 to 64 g/ml)
and tomatidine (0.08 to 40 M, 0.02 to 10 M). The use of combinations of the drugs at different
concentrations enables determination of a fractional inhibitory concentration (FIC) index, as described in
reference 48. Drug combinations that give rise to a growth reduction of more than 50% are then
identiﬁed, and the associated FIC index determines the properties of the combination. A FIC index of
between 2 and 0.5 indicates an additive effect, while a FIC index of 0.5 indicates a synergetic effect.
Average values were calculated from three replicates.
(ii) Antifungal serial dilution susceptibility assay. Drug susceptibility testing was also performed
on solid YEPD agar plates containing speciﬁc drug concentrations or vehicle (1% DMSO). Tenfold serial
dilutions of cells were spotted starting with a cell concentration of 106 cells/ml. Assays were performed
at least in duplicate.
(iii) Antifungal bioﬁlm susceptibility assay. Antifungal susceptibility tests were conducted on C.
albicans bioﬁlms according to a published protocol (49) with 48 h of bioﬁlm formation and 48 h of
antifungal treatment. Brieﬂy, an aliquot of a 100-l cell suspension (106 cells/ml) per well prepared in
RPMI medium with 0.2% glucose (pH 7) was deposited in each well of a 96-well plate, and the plate was
incubated at 37°C for 48 h to allow bioﬁlm formation. The wells were then washed twice with
phosphate-buffered saline (PBS). Twofold serial dilutions of the compounds with concentrations ranging
from 50 to 1.56 g/ml were prepared, and the compounds were added to the wells containing the
bioﬁlms. The plates were incubated again for 48 h at 37°C and then washed twice with PBS. Measure-
ment of the metabolic activity of the sessile cells was performed using a colorimetric assay with
2H-tetrazolium,2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-hydroxide salt (XTT;
catalog number X4626; Sigma-Aldrich). The plates were read with a spectrophotometer plate reader at
492 nm. The MIC was deﬁned as the drug concentration at which the optical density value was equal to
or less than 50% of the one for the drug-free bioﬁlm. Assays were performed in duplicate.
(iv) Antifungal drug time-kill assay. The time-kill assay was performed as follows. Cells were
cultured overnight in YEPD at 30°C, adjusted to 2  105 cells/ml in YEPD, and submitted to the
corresponding concentration of the drugs, their combination, or the solvent. After 0, 4, 8, and 24 h of
incubation with the drug at 30°C under agitation in a 3-ml liquid volume, cell viability was determined
by plating the cells on a YEPD agar plate for 16 h at 34°C and counting the number of CFU of the colonies.
The drug was determined to have a fungicidal effect when at least a 2-fold log decrease in the number
of CFU per milliliter from the initial cell density was measured.
(v) Antibacterial susceptibility assay. Antibacterial susceptibility testing was carried out on the
basis of CLSI approved standard M7-A7 using the microdilution method with cation-adjusted Mueller-
Hinton (CAMH) broth. Brieﬂy, overnight Escherichia coli (ATCC 25922) cell cultures were adjusted to a
McFarland 0.5 standard (108 cells/ml) with NaCl. The ﬁnal cell concentration was 3 105 CFU/ml. Twofold
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serial dilutions of the drugs at concentrations ranging from 64 g/ml to 2 g/ml were prepared. The
microplates were incubated at 37°C for 24 h, and then the MICs were read with a spectrophotometer
plate reader at 450 nm. The MIC was deﬁned as the drug concentration at which the optical density was
equal to or decreased more than 50% from that of the drug-free culture. Assays were performed in
duplicate. Drugs were tested at the pH at which antifungal activity was detected during the microdilution
susceptibility screen (pH 7 was used if the drug was active at both pH values).
Cell cytotoxicity assay. A cell cytotoxicity assay were performed according to a standard procedure
with sulforhodamine B (SRB) as the reporter (50). HeLa cells (CCL-2; ATCC, Manassas, VA, USA) were
cultured in Dulbecco modiﬁed Eagle medium with 10% fetal bovine serum at 37°C with 5% CO2.
Ninety-six-well plates were ﬁlled with a seeding density of 104 cells/well. After 24 h of growth (day 1), the
cells were washed twice with PBS, 2-fold serial dilutions (starting at 100 g/ml) of the compounds were
added to the cells, and the cells were incubated for 48 h. The starting amount of cells was monitored by
ﬁxing the cells on day 1. On day 3, all cells were washed twice with PBS and then ﬁxed and labeled as
described above for the standard procedure. The optical density at 492 nm (OD492) was measured, and
the percentage of cells killed could be determined using the following formula: 100  (OD on day 3/OD
on day 1)  100. The 50% lethal dose (LD50) corresponded to the concentration at which at least 50%
of the cells were killed. Assays were performed in duplicate. The selectivity index (SI) was then calculated
by dividing the LD50 by the MIC against C. albicans.
Hierarchical clustering of activity proﬁles. The MICs of the 40 NPs active against the 7 yeast strains
were used to generate the heatmap, and the pH of the activity was indicated by use of a color scheme.
NPs that showed activity at both pHs were labeled as being active at neutral pH. Cluster analyses were
performed by calculating the distance matrix using the Euclidean method, followed by Ward (Ward.D)
hierarchal clustering using the gplots package in R (version 3.3.2).
Calcoﬂuor white staining. Yeast cells were grown overnight and washed twice with PBS. Cells (105)
were resuspended in 200 l RPMI medium with 0.2% glucose in a 96-well plate and incubated for 3 h
at 37°C. Ten microliters of calcoﬂuor white stain (Sigma-Aldrich) was added to the well. After 10 min at
room temperature, 4 l of the cell suspension was mixed with 2 l of Mowiol mounting medium
(Sigma-Aldrich), and directly thereafter, ﬂuorescence microscopy was performed with a Zeiss Axioplan 2
microscope (Zeiss, Oberkochen, Germany).
Sterol content analysis. (i) Total sterol extraction. About 2  105 cells/ml were cultured for 16 h
at 30°C under agitation in 15 ml YEPD supplemented with tomatidine at the concentrations indicated
above (and with DMSO at a ﬁnal concentration of 1%). The cells were treated with trichloroacetic acid
(TCA) to a ﬁnal concentration of 5% to stop metabolism, and the cells were incubated for 10 min on ice.
Harvested cells were then washed twice: ﬁrst in 5% TCA in distilled water and then in distilled water to
remove the traces of the YEPD medium. The cells were resuspended in 3 ml of distilled water, and 109
cells were used to perform total sterol extraction, as described in reference 51, and to determine the
amounts of total cellular sterols (esteriﬁed and nonesteriﬁed). The cells were resuspended in 1 ml 60%
KOH in a screw-cap glass tube, to which 1 ml of 0.5% pyrogallol-containing methanol and 1 ml of
methanol were added. The tubes were heated at 85°C for 2 h and returned to room temperature. The
sterols were extracted three times with 2 ml of petroleum ether (high boiling point). The combined
petroleum ether phases were dried under an N2 ﬂow, resuspended in 1:1 (vol/vol) methanol-chloroform,
and sonicated for 5 min for further analysis by gas-liquid chromatography–mass spectrometry (GLC-MS).
(ii) GLC-MS analysis. Sterols were analyzed by GLC-MS as described in reference 51. ERG4 and ERG6
deletion mutant extracts were used to determine the positions of the known sterols.
Tomatidine formulation. A nanosuspension was obtained by adding 6 mg of tomatidine, 300 l 2%
(wt/vol) D--tocopherol polyethylene glycol 1000 succinate (TPGS; Sigma-Aldrich) as a stabilizer, and 700
l of puriﬁed water as a nonsolvent in a 2-ml tube (tomatidine-TPGS [50:50]). Wet milling with 579 mg
of zirconium beads (tubes preﬁlled with 2.0 ml 0.5-mm zirconium beads, triple pure, high impact;
BeadBug; Sigma-Aldrich) was performed for 70 h on a Genie 2 vortex apparatus. Then, the nanosuspen-
sions were frozen by dipping the tubes in liquid nitrogen. Subsequently, the nanosuspensions were
lyophilized for 48 h using a Christ Alpha 2-4 LD Plus freeze-dryer. The particle size distribution was
determined by dynamic light scattering (DLS) using a Zetasizer 3000HSA particle analyzer. The samples
were dispersed in a 9/10 volume of ﬁltered puriﬁed water and stirred for 20 min with a vortex mixer to
ensure a uniform dispersion free of aggregates. A 1/10 volume of 10 PBS was added prior to injection.
Transmission electron microscopy (TEM). C. albicans strain CAF2-1 was grown in YNB liquid
cultures for 2 h at 37°C (in 15-ml plastic tubes). Next, miconazole (1 mg/ml in DMSO) was added at a
concentration of 10 g/ml, and the cultures were grown for 18 h to evaluate the cytotoxic effect of this
commercial product on the yeast strain. The cytotoxic effect of tomatidine was evaluated by use of the
same experiment, except that this compound (1 mg/ml in DMSO) was added at a concentration of 20 M
and the cultures were grown for 18 h. Cells were prepared as described in reference 12. Thin sections
were observed with a transmission electron microscope (Philips CM10) with a Mega View II camera.
Control cells were obtained in the same way but did not receive drug treatment.
Selection of NPs. A smart chemical library containing 199 natural products (NPs) with potential
antifungal activity was constructed. Among these compounds, 53% were previously isolated from crude
plant extracts that presented antifungal activity. The bioguided process of isolation of these compounds
was performed by bioautography using wild-type and genetically modiﬁed strains of C. albicans (12). In
parallel, NPs with (i) structures closely related to those of NPs possessing antifungal activity from
published sources and (ii) unknown antifungal activity were selected from commercial catalogues and
acquired (the compounds are listed in Table S1 in the supplemental material). The identity and the purity
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of the commercial compounds obtained were systematically determined by nuclear magnetic resonance
(NMR) and high-resolution mass spectrometry (HRMS) analysis.
Genome-wide transcriptional analysis. (i) RNA extraction and processing. An overnight YEPD
culture of the C. albicans SC5314 strain was diluted 1:200 in 5 ml YEPD medium and incubated under
agitation at 30°C until early exponential growth phase (OD540  0.3). Fifty microliters of solvent (DMSO)
or 250 M tomatidine (diluted in DMSO) was added to the culture to reach a concentration of 1% DMSO
and 2.5 M tomatidine. Total RNA was extracted after 1 or 3 h tomatidine-solvent exposure by
mechanical disruption of the cells with glass beads as previously described (52). Experiments were
carried out in triplicate with 12 samples. Total RNA extracts were treated with DNase using a DNA-free
kit (Ambion-Life Technologies, Zug, Switzerland), and RNA quality and integrity were veriﬁed with a
fragment analyzer automated CE system (Advanced Analytical). One microgram of RNA was used to
create sequencing libraries through a standard Illumina TruSeq stranded mRNA protocol. Each library
(sample) received a different index, enabling several libraries to be multiplexed. Before RNA sequencing,
the libraries were analyzed with a fragment analyzer to assess their quality and fragment size and with
a Qubit ﬂuorometer (Invitrogen) to determine the cDNA concentration. Libraries were kept at20°C until
sequencing.
(ii) RNA sequencing. The 12 libraries were run on an Illumina HiSeq platform (HiSeq2500). Sequenc-
ing data were processed using Illumina Pipeline software. Reads were ﬁltered and trimmed, and the
counts were aligned to the C. albicans SC5314 reference genome using the CLC workbench pipeline. The
number of read counts per gene locus was extracted.
(iii) RNA-seq data analysis. Data normalization and gene expression analysis were performed in R
(version 3.2.3), using Bioconductor packages (as described in reference 24). The read count data were
normalized using the TMM (trimmed mean of M values) method available in the R package edgeR (53)
and transformed into log2 counts per million by the Voom method from the R package Limma (54). This
package was then used to apply a linear model with one factor per condition (4 conditions, consisting
of untreated for 1 h, tomatidine treated for 1 h, untreated for 3 h, and tomatidine treated for 3 h [all in
triplicate]) to the transformed data. Two contrasts representing the difference between tomatidine-
treated and untreated cells at each drug exposure time (1 and 3 h) were extracted from the linear model
to result in a moderated t statistic for all genes expressed.
qPCR analysis. Total RNA (the same RNA samples used for the RNA-seq experiments; 12 samples
representing 4 conditions in 3 biological replicates) were treated with DNase, and 1 g of treated RNA was
used as the template for cDNA synthesis using a high-ﬁdelity cDNA synthesis kit (Roche Diagnostics,
Switzerland). To determine relative gene expression, real-time quantitative PCR (qPCR) was performed using
primers, TaqMan probes (modiﬁed with 6-carboxyﬂuorescein and 6-carboxytetramethylrhodamine), and
iTaq supermix with carboxy-X-rhodamine (Bio-Rad AG, Switzerland) in a StepOnePlus real-time PCR
system (Applied Biosystems-Life Technologies, Switzerland). Each reaction was run in duplicate. The
primers and probes are listed in Table S3. Relative transcript quantities were assessed using the 2ΔΔCT
threshold cycle (CT) method (55) to determine the level of expression, which was normalized to that of
ACT1 as a reference gene.
C. albicans ERG6 deletion strain construction. To delete the ﬁrst allele of ERG6, two fragments of
571 bp and 569 bp of the ﬂanking 5= and 3= untranslated regions, respectively, were PCR ampliﬁed from
SC5314 DNA with the following primer pairs: primer pair ERG6_5For_KPN1 and ERG6_5Rev_Xho1 and
primer pair ERG6_3For_SacII and ERG6_3Rev_SacI. These primers contain restriction sites in order to
insert the two amplicons sequentially in pSFS2A (56). The plasmid obtained (pSD1) was then digested
with ScaI and transformed into C. albicans SC5314. The yeasts were transformed by a lithium acetate
procedure described previously (57).
Transformants were positively selected on a YEPD plate containing 200 g/ml nourseothricin (Nour;
Werner Bioagents, Germany). The Nour selective cassette was then removed by growing cells in YEPD
medium containing 2% maltose. Nour-susceptible cells were used to delete the second allele. The same
strategy was repeated for the second allele, but in order to achieve it, a different 3= end region
homologous to ERG6 (at the end of the coding DNA sequence [CDS] and upstream of the ﬁrst allele, 343
bp) was ampliﬁed with primers ERG6_3CDSFor_SacII and ERG6_3CDSRev_SacI. The resulting construct
was named pSD4.
Nour-resistant transformants were phenotypically screened using a simpliﬁed ergosterol extraction
and detection method (58). An alteration of the expected UV spectrophotometric sterol proﬁles was
detected in some transformants, with an additional peak of absorbance at 230 nm indicating a
perturbation in the ergosterol pathway and thus suggesting the deletion of the second ERG6 allele.
GLC-MS analysis conﬁrmed the loss of ERG6 function, with zymosterol being the most abundant sterol
(data not shown).
S. cerevisiae forward genetic screen. (i) Deletion of MSH2 in S. cerevisiae DSY4743. The MSH2
PDR5 deletion strain was constructed from a PDR5 deletion strain (DSY4743) using a PCR-based gene
deletion approach described previously (61). Primers For_msh2_Sc and Rev_msh2_Sc were used to
amplify the HIS3 selection marker. The HIS3-containing amplicons were puriﬁed using a NucleoSpin gel
and PCR cleanup kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s instructions and
used to transform S. cerevisiae pdr5Δ (DSY4743) using the standard lithium acetate protocol.
(ii) Selection of resistant mutants. Overnight cultures of cells of the msh2Δ prd5Δ strain (strain P1)
were plated on solid medium containing one of several tomatidine concentrations and incubated for 2
to 7 days. One pop-out mutant (mutant R1) was identiﬁed, and resistance to tomatidine was conﬁrmed
using the MIC broth dilution method. The other tomatidine-resistant strains were identiﬁed as described
previously by Ojini and Gammie (29) with few modiﬁcations. The msh2Δ prd5Δ strain (P1) was grown to
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saturation in 5 ml of YEPD medium at 30°C. Overnight cultures were diluted 1:200 in YEPD medium
containing 50 g/ml of ampicillin and grown in the presence of 10 M tomatidine in 96-well microtiter
plates (Costar) in a shaking incubator at 30°C for 72 h. The cells were diluted 1:200 in the respective
medium, distributed into new 96-well plates, and grown for 48 h at 30°C in the absence of the drug. The
cultures were then diluted 1:200 in medium containing tomatidine in a new 96-well plate, and the optical
density at 540 nm was recorded at six different time points (0, 16, 20, 24, 38, and 42 h) over a 42-h period.
The isolates in several wells were selected on the basis of their growth proﬁles with a high optical density
in the presence of drug after 40 h, plated onto YEPD containing 7.5 M tomatidine, and incubated for
4 days at 30°C. Resistant pop-outs were cultured overnight, and resistance was retested by the broth
dilution method. Four resistant strains arising from 2 different cultures (strain R2 and strains R3.1, R3.2,
and R3.3) were identiﬁed and, together with the R1 mutant, submitted to whole-genome sequencing.
(iii) Whole-genome sequencing. Cells of the ﬁve tomatidine-resistant mutants and the parental
strain were grown overnight in YEPD medium at 30°C under constant agitation. Genomic DNA was
extracted from the yeast using a Gentra Puregene yeast/bacteria kit (Qiagen, Hilden, Germany) with
RNase treatment. The DNA concentration was veriﬁed by use of a Qubit (version 2.0) ﬂuorometer
(Thermo Fisher) and adjusted to 10 ng/ml for whole-genome sequencing. DNA quality was veriﬁed with
a fragment analyzer (Advanced Analytical Technologies, Ankeny, IA, USA). Whole-genome sequencing
was performed at Fasteris SA (Plan-les-Ouates, Switzerland) using a TrueSeq Nano DNA library preparation
and an Illumina MiSeq system. Paired-end reads of 250 bp were performed, giving an average coverage of
each genome of 118 times. The sequencing data were analyzed using the CLC Genomics Workbench (version
9.5.2) program (Qiagen). The sequence reads were mapped to the S288C reference genome. The average
percentage of mapped reads was 93%. Mutations were identiﬁed using the variant detector option by
comparing the sequences of the genomes of the P1 and tomatidine-resistant strains to the sequence of the
reference genome. The functional consequences option was used to identify amino acid changes. To identify
mutations speciﬁc to the resistant strains, the sequences of the variants of the tomatidine-resistant strains
were compared to the sequence of the P1 strain using the compare variants option. Only nonsynonymous
mutations were taken into account, with a frequency of 50% of reads for insertions and deletions (indels)
and a frequency of 90% of reads for single nucleotide variants (SNV) being used.
(iv) Construction of S. cerevisiae ERG6 point mutant strains. To introduce speciﬁc point mutations
into ERG6 in S. cerevisiae, a clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9
genome editing system was used as described previously (31). All primers are listed in Table S3. A
20-nucleotide guide sequence was selected using an online tool named CHOPCHOP (http://chopchop
.cbu.uib.no/). PAM 11 (position 251849) and PAM 19 (position 252596) were chosen for the D249G
mutation (position 252245) and G132D mutation (position 252596), respectively. The two repair frag-
ments were constructed as described previously (59). All fragments were puriﬁed using a NucleoSpin gel
and PCR cleanup kit (Macherey-Nagel).
Genome editing was performed by cotransformation of the pMEL10 guide and the repair fragments into
S. cerevisiae IMX581, and selection was carried out in YNB agar lacking uracil. Veriﬁcation that the mutations
were introduced was performed by PCR ampliﬁcation of ERG6 (with primers Erg6_verif_for and Erg6_verif_rev;
Table S3) and by sequence analysis as described above. The guide RNA plasmid pMEL10 were removed by
counterselection pressure with 5-ﬂuoroorotic acid (5-FOA; Toronto Research Chemicals [TRC]), and the effect
of the mutations on tomatidine susceptibility was veriﬁed by the broth dilution method.
Mouse experiments and ethics statement. All animal experiments were performed at the Univer-
sity Hospital Center of Lausanne, Lausanne, Switzerland, with approval through the Institutional Animal
Use Committee, Affaires Vétérinaires du Canton de Vaud, Switzerland (authorization no. 1734.3), accord-
ing to decree 18 of the federal law on animal protection. Female BALB/c mice (age, 8 weeks; Charles River
France) were housed in ventilated cages with free access to food and water. The SC5314 strain was
grown overnight under agitation at 30°C in YEPD medium, subsequently diluted 100-fold in YEPD
medium, and grown again overnight under agitation at 30°C. Overnight cultures were washed twice with
PBS and resuspended in 5 ml PBS. The concentration of each culture was measured by determination of
the optical density, and each strain was diluted in PBS to the desired concentration (4  105 CFU/ml).
Mice were injected through the lateral tail vein with 250 l of a cell suspension containing 1.6  106
cells/ml. At 7, 24, and 31 h postinfection, a tomatidine formulation or placebo was administered by
intraperitoneal (i.p.) injection in a volume of 200 l. At 48 h postinfection, the kidneys were recovered
and weighed, and the number of CFU was determined as previously described (60). The number of CFU
per gram of kidney was determined. Outlier analysis was ﬁrst performed in GraphPad Prism software
using default parameters (robust regression and outlier removal [ROUT] with a coefﬁcient Q  1%), and
the ﬁnal number of individuals per group was 10 for placebo-treated mice and 9 for tomatidine-treated
mice. Statistical analyses of the differences between the numbers of CFU were performed using the
Mann-Whitney test. The weight and temperature of the animals were monitored daily.
Accession number(s). All reads were deposited in the Gene Expression Omnibus (GEO) database
under accession number GSE96965. Genome data have been deposited at NCBI under BioProject
accession number PRJNA380059.
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